Skip to main content

VERU

Stock
Health Care
Biotechnology

Performance overview

VERU Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Company info

SectorHealth Care
IndustryBiotechnology
Employees152
Market cap$134.4M

Fundamentals

Enterprise value$69.1M
Revenue$16.9M
Revenue per employee
Profit margin-215.24%
Debt to equity16.10

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.22
Dividend per share$0.28
Revenue per share$0.12
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+3.9
Credit+3.2
Liquidity-0.1
Inflation+1.2
Commodities-0.2
Interest Rates+0.6

Valuation

Dividend yield47.35%
PEG Ratio-2.09
Price to sales5.27
P/E Ratio-2.09
Enterprise Value to Revenue4.09
Price to book4.21

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend dayApril 28, 2014

News

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Penny stock Veru Inc. VERU on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patients over 60 years receiving Novo Nordisk A/S' NVO Wegovy (semaglutide) for chronic weight management.

Benzinga (May 28, 2025)
Here's Why Veru (VERU) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research (March 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free